Food & Drug Law Institute Conference on Products Liability For FDA Regulated Products January 26, 2005 Recalls: The First Smoke of A Mass Tort Overview.

Slides:



Advertisements
Similar presentations
FDA’s Proposed Rule under FSMA for Preventive Controls
Advertisements

North Carolina Department of Agriculture and Consumer Services Food and Drug Division 4000 Reedy Creek Road Raleigh, NC Harold McDowell, RS Food.
Reprocessing Biotech Products
ALERT: The Basics Food and Drug Administration Center for Food Safety and Applied Nutrition.
Complying with FSMA: What a cashew exporter to the U.S. needs to do.
1 OSHA FEDERAL OCCUPATIONAL SAFETY AND HEALTH ACT (OSHA) OF 1970 George Mason University College of Nursing and Health Science Regulatory Requirements.
Capturing and Reporting Adverse Events in Clinical Research
John Naim, PhD Director Clinical Trials Research Unit
Field Investigators: ADE Detectives. Section One Introduction to the Team and Their Roles.
Pilot Risk-Ranking Model to Prioritize Manufacturing Sites for GMP Inspections Advisory Committee for Pharmaceutical Science Manufacturing Subcommittee.
External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.
Arnold Best Recall Coordinator U. S. Food & Drug Administration.
Weaving regulations into sound value analysis processes Barbara Strain, MA, SM(ASCP) Director Value Management University of Virginia Health System.
Top Tactics for Maximizing GMP Compliance in Blue Mountain RAM Jake Jacanin, Regional Sales Manager September 18, 2013.
FDA MedWatch and Patient Safety. Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006  The Act defines a ‘serious adverse event’
Module 5 | Slide 1 of 22 January 2006 Sections 5 and 6 Basic Principles of GMP Complaints and Recalls.
Are you ready for a recall? Medical Device Regulatory, Reimbursement and Compliance Congress March 28, 2007 Willie R. Bryant, Jr. Consultant Stericycle,
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
FDA Regulatory Considerations in Launching Products Michael A. Swit, Esq. Vice President, Life Sciences WITI (Women In Technology International) San Diego.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Module 5Slide 1 of 24 WHO - EDM Part One, Sections 6 and 7 Basic Principles of GMP Complaints and Recalls.
A royal decree was issued on Feb.13, 2007 assigned the responsibility for regulating medical devices, in vitro diagnostic devices, prescription eye glasses,
Project co-financed by European Union Project co- financed by Asean European Committee for Standardization Implementing Agency 1 Module 13 GMP Workshop.
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
What is Food Recall A food recall is a voluntary action by a manufacturer or distributor to protect the public from products that may cause health problems.
A CASE OF RECALL POLICY AND ITS APPLICATIONS OCCURRED IN A COMPANY THAT PRODUCES AND PACKAGES PASTEURIZED MILK Alejandra Colina Ibarra University of Guelph.
Annette Krawczyk-Sheets Professor Anne-Marie Yerks English Composition 106 Online 15 December 2010.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Food and Drug Administration
Top 10 Medical Device Citations
Module 5 | Slide 1 of Sections 5 and 6 Basic Principles of GMP Complaints and Recalls.
Risk Management - the process of identifying and controlling hazards to protect the force.  It’s five steps represent a logical thought process from.
The International Pharmaceutical Compliance Summit on Medical Affairs, Clinical Trials, Safety and Publication Philadelphia, Pennsylvania March 31, 2005.
Introduction to Workplace Safety
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.
COMPLIANCE ACTIONS FDA Regulation & Licensure of Whole Blood & Blood Components, Including Source Plasma September 15-16, 2009 Helen Cowley Office of Compliance.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
Ergonomics Regulatory Requirements Bawan Saravanabawan, Labour Program, HRSDC February 4, 2008.
This class cannot be shared or copied without the written permission of PracticeWorks Systems, LLC.
Project co-financed by European Union Project co- financed by Asean European Committee for Standardization Implementing Agency 1 Module 12 GMP Workshop.
Proposed Rule for Preventive Controls for Animal Food.
Proposed Rule: 21 CFR 507 Proposed Rule for Preventive Controls for Animal Food 1.
Overview of FDA's Regulatory Framework for PET Drugs
Reclaimed Wastewater Quality Criteria, Standards, and Guidelines
Rules for Supporting Part 803 and Part 806 Decision Making Page 1 Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports.
FDLI 49 th Annual Conference Washington, D.C. April 7, 2006 THE FUTURE OF COMPLIANCE GOVERNANCE Michael A. Swit, Esq. Vice President, Life Sciences.
Pharmaceutical post operational activities
Pharmaceutical post operational activities
FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,
Basic Principles of GMP
Product Recall Laws in China Xiangwen Liu Partner King & Wood PRC Lawyers.
Awareness Training: ‘HARPC’ for Food Safety Complimentary Presentation by Quality Systems Enhancement 1790 Wood Stock Road Roswell GA E. mail:
Complaint and recall 1. Title 21--food and drugs Chapter I- food and drug administration department of health and human services Subchapter A- General.
Office of Food Safety and Recall Food Safety Investigation and Recall Presented by: Francis Lindsay, CFIA Technical Specialist Querétaro, México, October.
Recalls and Field Corrections IMDMC FDA Regulatory 102 May 19, 2016.
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.
© 2009 Michigan State University licensed under CC-BY-SA, original at Incident Management.
KEVIN BEDAL LISA CARLIN MATT CARROLL ERIN NICHOLS Product Safety & Failure Analysis.
FSMA TRAINING Industry Recall Readiness BEST PRACTICES.

By Rebecca Moulder GRIT 700
Recalls Neisa M. Alonso Emergency Response Coordinator US FDA / SJN-DO
Developing a Recall Plan for Meat and Poultry Products
Linda M. Chatwin, Esq. RAC Business Manager, UL LLC
Presentation transcript:

Food & Drug Law Institute Conference on Products Liability For FDA Regulated Products January 26, 2005 Recalls: The First Smoke of A Mass Tort Overview of a Recall of an FDA-Regulated Product Michael A. Swit, Esq. Vice President, Life Sciences

My Objectives Today Review key rules or requirements that apply to recalls –What is a recall and what is not –What FDA’s authority is relative to recalls – e.g., can it order a recall? –How FDA deals with recalls and how industry interacts with the agency, including information FDA expects from a recalling firm How FDA expects public notification to be handled Classifying recalls by health hazard profile –Handling the recall logistically Understand how recall handling can set the tone for potential products liability exposure post-recall

Defining “Recall” Recall means a firm`s removal or correction of a marketed product that the Food and Drug Administration considers to be in violation of the laws it administers and against which the agency would initiate legal action, e.g., seizure. Recall does not include a market withdrawal or a stock recovery. 21 CFR 7.3(g)

Defining …“Correction” Correction means repair, modification, adjustment, relabeling, destruction, or inspection (including patient monitoring) of a product without its physical removal to some other location. 21 CFR 7.3(h)

Defining … “Market Withdrawal” Market withdrawal means a firm`s removal or correction of a distributed product which involves a minor violation that would not be subject to legal action by the Food and Drug Administration or which involves no violation, e.g., normal stock rotation practices, routine equipment adjustments and repairs, etc. 21 CFR 7.3(j)

Defining … “Stock Recovery” Stock Recovery – a firm’s removal or corrections of a product that has not been marketed or that has not left the direct control of the firm, i.e., the product is located on the premises owned by or under the control of the firms and no portion of the lot has been released for sale or use.

Defining … “Recall Strategy” A planned specific course of action to be take in conducting a specific recall, which addresses the depth of the recall, need for public warnings, and extent of effectiveness checks for the recall. 21 CFR 7.3(l)

Defining … “Recall Classification” The numerical (Roman) designation, i.e., I, II, or III, assigned by FDA to a particular product recall to indicate the relative degree of health hazard presented by the product being recalled. Class I – a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.

Defining … “Recall Classification” … Class II – a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Class III – a situation in which use of, or exposure to, a violative product is not likely to cause adverse consequences.

Classification – Evaluating Health Hazard – 21 CFR 7.41 You must do it; and FDA also will do it and its decision will govern; rarely reversed Factors addressed in a Health Hazard Evaluation (“HHE”) –Has disease or injury occurred due to use of (violative) product? –Could existing conditions contribute to a clinical situation that could expose humans (or animals) to a health hazard? –How will the hazard impact (e.g., differently) various population segments?

Classification – Evaluating Health Hazard … Factors addressed in HHE… –Degree of seriousness of HH to which at risk populations would be exposed –Assessment of likelihood hazard will occur –Assessment of consequences – immediate or long- term – if hazard occurs

Can FDA Make You Recall? General rule: No. But, FDA: “if we request, we will seize if you don’t” –FDA Regulatory Procedures Manual (RPM) – if FDA requests, it is usually a Class I scenario Statutory and regulatory exceptions: –Infant formula –Medical Device recall/notification authority – §518(e) –Biological products under the National Childhood Vaccine Safety Act of 1986 –Human tissue – 21 CFR

Do You Have to Tell FDA You’re Doing A Recall? Technically – not always –“Exceptions” involving notice that will trigger recall as an issue for you and FDA Field Alert – 21 CFR (b)(1) – 3 working days notice to your local FDA district office any time NDA holder learns: –Info that its drug or labeling could be mistaken for, or applied to another article (e.g., label mix-ups) –Info about: »Any bacteriological contamination »Any significant chemical, physical or other change or deterioration in distributed drug; or »Any failure of a batch to meet its specification ANDA Stability Commitment – signed part of ANDA that you will recall any batch that falls out of specification.

Do You Have to Tell FDA You’re Doing A Recall … –“Exceptions” … PMA Conditions of Approval – must report to FDA within 10 days after the applicant receives or has knowledge of information concerning: –A mix-up of the device or its labeling with another article. –Any adverse reaction, side effect, injury, toxicity, or sensitivity reaction attributable to the device and: »not addressed by the device's labeling; or »addressed by device labeling but occurring with unexpected severity or frequency. –Any significant chemical, physical or other change or deterioration in the device, or any failure of the device to meet the specifications established in the approved PMA that could not cause or contribute to death or serious injury but are not correctable by adjustments or other maintenance procedures described in the approved labeling Practically – yes; FDA expects it

Information FDA Expects On a Recall That Could Come Back to Haunt You Sources: –GUIDANCE FOR INDUSTRY – Product Recalls, Including Removals and Corrections. –Regulatory Procedures Manual. March Chapter 7. Recall Procedures. Be very careful – this information will be discoverable

Information FDA Wants in a Recall Submission … Reason for Recall (Guidance Item #A-6) –How product is defective or violative –How defect affects performance or safety –How the problem occurred and when –How discovered and when –Complaints associated with product/problem Health Hazard Evaluation – (Guidance Item #A-7) -- your assessment of health risk associated with “deficiency”

Information FDA Wants in a Recall Submission … Recall Strategy (Recall Guidance #A-10) – –Depth of recall – wholesaler, retail, consumer –Notification process –Effectiveness check strategy Public Notification (Recall Guidance, Part B) –Press release – “usually appropriate” if a significant health hazard and recalled product in hands of consumers Consult with district office recall coordinator before issuing “whenever possible”

Recall Effectiveness Checks Level A – 100% of consignees Level B – between 10% and <100% of consignees Level C – 10% Level D – 2% Level E – no checks

Evaluation of Recall Per Recall Guidance (Item C), FDA expects you to take two additional key steps after your recall: –Root Cause Analysis –Corrective Action Plan to prevent future occurrences

Timing Rules FDA –Field Alerts – 3 “working” days –PMA Reports – 10 days SEC –8-K’s – for certain specified and “other events” – supposed to implement SOX "real time issuer disclosure" requirement – within 4 business days of the event General good sense – correlate to health hazard

Vioxx – Recall, Correction or Withdrawal? Not a correction – did not remain on market Not a recall – no allegation to date by FDA or recalling firm that legal violation occurred Market Withdrawal –Based on (publicly available) knowledge at time Merck acted, this is the closest definition –Consistent with FDA contemporaneous descriptions at the time, which did not use “recall”

Questions? Call, , fax or write: Michael A. Swit, Esq. Vice President, Life Sciences THE WEINBERG GROUP INC. 336 North Pacific Coast Hwy. 101 Suite C Encinitas, CA Phone Fax Cell D.C. Office

For more than twenty years, leading companies have depended on THE WEINBERG GROUP when their products are at risk. Our technical, scientific and regulatory experts deliver the crucial results that get products to market and keep them there.